BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing
MWN-AI** Summary
Bon Natural Life Limited (NASDAQ: BON), a prominent player in the bio-ingredient sector for natural health and personal care, has announced a strategic partnership with the Shaanxi Chang'an Pilot Life Science Industry Innovation Center. This collaboration led to the inception of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing, which was inaugurated on December 18, 2025.
The Joint Laboratory aims to pioneer research and development in bio-manufactured natural active ingredients tailored for functional foods and personal care products. By integrating advanced techniques such as fermentation-based biosynthesis, natural compound isolation, and artificial intelligence for process optimization, the laboratory seeks to enhance production efficiency, supply reliability, and environmental sustainability when compared to traditional plant-based extraction methods.
Founded in 2006, BON has established a robust portfolio that includes plant-derived extracts and functional ingredients, catering to diverse markets, including China, North America, the EU, Japan, and South Korea. Notably, BON's expertise in extraction and biosynthesis is bolstered by a proprietary, AI-driven R&D platform that marries data analytics with scalable production processes.
Chang'an Pilot, relatively new, was founded in 2022 with an emphasis on life sciences and AI-enabled manufacturing technologies. The infrastructure and research services provided by Chang'an Pilot are expected to enrich the laboratory's endeavors.
Yongwei Hu, Chairman of BON, expressed optimism about this initiative, stating that it will fortify research capabilities and foster significant collaboration, ultimately driving the development of high-quality, scalable natural ingredients while reinforcing the company's long-term growth strategy.
MWN-AI** Analysis
Bon Natural Life Limited's (NASDAQ: BON) recent partnership with Chang'an Pilot to establish a Joint Laboratory for Natural Ingredients and Bio-Manufacturing signals a pivotal move in the natural health and personal care sectors. This collaboration emphasizes research and development (R&D) capabilities, focusing on bio-manufactured natural active ingredients that harness fermentation-based biosynthesis and artificial intelligence.
For investors, this partnership underscores BON's commitment to innovation and sustainable production practices, positioning the company favorably in a marketplace increasingly driven by consumer demand for environmentally friendly and reliable ingredient sourcing. Notably, the R&D advancements are expected to enhance production efficiency and supply reliability compared to traditional extraction methods—key factors that can boost competitiveness and profit margins.
Given that BON already serves a diverse international market, this laboratory could provide a crucial edge in maintaining its status as an industry leader. With the integration of AI in manufacturing processes, BON is likely to achieve scalable solutions that can reduce costs and optimize resource use, appealing to environmentally conscious consumers.
On the financial front, while BON has established a strong market presence, the sustainable production capabilities derived from this partnership are expected to attract further investment and enhance market valuation. Potential investors should keep a close eye on the company's future growth initiatives stemming from this laboratory, as successful product development can lead to increased revenue streams and market penetration.
However, it is essential to approach this opportunity with a balanced perspective. Investors should consider market risks and monitor developments related to regulatory changes, competition, and the broader economic environment impacting consumer spending in health and personal care. Overall, this strategic alliance positions BON for long-term growth, but careful evaluation of the evolving landscape is prudent.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
XI'AN, China, Feb. 17, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot").
The Joint Laboratory will focus on the research and development of bio-manufactured natural active ingredients for use in functional foods and personal care products. Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled process optimization, the Joint Laboratory is intended to support the Company's efforts to improve production efficiency, supply reliability, and environmental sustainability compared to traditional plant-based extraction methods.
Founded in 2006, BON operates in the development, manufacturing, and commercialization of natural active ingredients for applications in health and personal care products. The Company's product portfolio includes plant-derived extracts, functional food ingredients, and personal care actives. BON serves customers in China, North America, the European Union, Japan, South Korea, and other international markets.
BON possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial intelligence-enabled bio-manufacturing research and development platform designed to integrate data analytics and process engineering for scalable production.
Chang'an Pilot, established in 2022, provides laboratory infrastructure and research services focused on life sciences and artificial intelligence-enabled manufacturing technologies.
Yongwei Hu, Chairman of BON, stated, "We believe the establishment of this Joint Laboratory will strengthen our research capabilities and create meaningful collaboration between our respective teams. We expect this initiative will support our continued efforts to develop scalable, high-quality natural ingredients and advance our long-term growth strategy."
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
SOURCE Bon Natural Life Limited
FAQ**
How does the establishment of the Joint Laboratory by Bon Natural Life Limited (BON) enhance the company's capabilities in bio-manufactured natural active ingredients compared to existing methods?
What specific roles will Bon Natural Life Limited (BON) and Chang'an Pilot play in the ongoing research and development efforts at the Joint Laboratory for Natural Ingredients?
Can Bon Natural Life Limited (BON) provide insights into the expected timeline for realizing production efficiency and sustainability improvements through this Joint Laboratory initiative?
How does Bon Natural Life Limited (BON) plan to leverage artificial intelligence in the Joint Laboratory to optimize processes for bio-manufacturing of natural ingredients?
**MWN-AI FAQ is based on asking OpenAI questions about Bon Natural Life Limited (NASDAQ: BON).
NASDAQ: BON
BON Trading
2.04% G/L:
$1.50 Last:
8,530 Volume:
$1.479 Open:
